Enliven Therapeutics (ELVN) Total Liabilities (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Total Liabilities data on file, last reported at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 19.53% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (down 19.53% YoY), and the FY2025 full-year result was $16.6 million, up 4.1% from the prior year.
• Total Liabilities slipped to $11.5 million in Q1 2026, from $16.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $26.0 million in Q4 2023 to a low of $1.8 million in Q3 2022.
• A 5-year average of $13.9 million and a median of $14.3 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 76.25% in 2022 and soared 576.18% in 2023, its largest moves.
• Tracing ELVN's Total Liabilities over 5 years: stood at $10.4 million in 2022, then soared by 150.25% to $26.0 million in 2023, then sank by 38.7% to $15.9 million in 2024, then gained by 4.1% to $16.6 million in 2025, then slumped by 30.67% to $11.5 million in 2026.
• Business Quant data shows ELVN's Total Liabilities at $11.5 million in Q1 2026, $16.6 million in Q4 2025, and $14.8 million in Q3 2025.